Wishlist (0)
Welcome visitor Login or Register.
My Cart    0 $0.00
Your shopping cart is empty!
Linifanib

Linifanib

0 reviews Write a review
Product Code: 3398
Availability: In Stock
$259.00
-+

Linifanib (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ with IC50 of 4 nM, 3 nM, 3 nM/4 nM and 66 nM respectively, mostly effective in mutant kinase-dependent cancer cells (i.e. FLT3). Phase 3.

Chemical Name 1-(4-(3-amino-1H-indazol-4-yl)phenyl)-3-(2-fluoro-5-methylphenyl)urea

Inhibitors Protein Tyrosine Kinase CSF-1R Linifanib 796967-16-3
Biological Activity:
Biological Activity Linifanib (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ with IC50 of 4 nM, 3 nM, 3 nM/4 nM and 66 nM respectively, mostly effective in mutant kinase-dependent cancer cells (i.e. FLT3). Phase 3.
Technical Data:
M.W. 375.41
Formula: <p>C<sub>21</sub>H<sub>18</sub>FN<sub>5</sub>O</p>
Solubility: DMSO
Purity: 98%
Storage: -20℃
CAS No: 796967-16-3
References:
References Albert DH, et al. Mol Cancer Ther, 2006, 5(4), 995-1006. Guo J, et al. Mol Cancer Ther, 2006, 5(4), 1007-1013. Hernandez-Davies JE, et al. Mol Cancer Ther, 2011, 10(6), 949-959. Jasinghe VJ, et al. J Hepatol. 2008, 49(6), 985-997. Albert DH, et al. Mol Cancer Ther. 2006, 5(4), 995-1006.

Write a review

Note: HTML is not translated!
    Bad           Good
Continue

About HDH PHARMA

At HDH Pharma, we are committed to offering our clients the highest quality research services with the most convenient and effective communications from both US and Indian operations. Clients in the Americas and Europe can pick up the phone and speak directly with our scientists in the US. Clients in Asia can receive the same rapid response from our scientists in India. HDH’s hybrid operation is designed with our client’s operational needs in mind.


Information

Extras

My Account

Powered By Nsoft Solutions
HDH PHARMA © 2024